123 related articles for article (PubMed ID: 9467046)
21. Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial.
Sarna G; Figlin R; Callaghan M
J Biol Response Mod; 1983; 2(4):343-7. PubMed ID: 6315898
[TBL] [Abstract][Full Text] [Related]
22. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
J Biol Regul Homeost Agents; 1993; 7(4):121-5. PubMed ID: 8023699
[TBL] [Abstract][Full Text] [Related]
23. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
Cebon J; Jäger E; Shackleton MJ; Gibbs P; Davis ID; Hopkins W; Gibbs S; Chen Q; Karbach J; Jackson H; MacGregor DP; Sturrock S; Vaughan H; Maraskovsky E; Neumann A; Hoffman E; Sherman ML; Knuth A
Cancer Immun; 2003 Jul; 3():7. PubMed ID: 12862418
[TBL] [Abstract][Full Text] [Related]
24. [A phase I study of recombinant interleukin 2 (S6820)].
Takaku F
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3271-6. PubMed ID: 3058043
[TBL] [Abstract][Full Text] [Related]
25. Clinical drug development: an analysis of phase II trials, 1970-1985.
Marsoni S; Hoth D; Simon R; Leyland-Jones B; De Rosa M; Wittes RE
Cancer Treat Rep; 1987 Jan; 71(1):71-80. PubMed ID: 3791270
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.
Abbruzzese JL; Levin B; Ajani JA; Faintuch JS; Saks S; Patt YZ; Edwards C; Ende K; Gutterman JU
Cancer Res; 1989 Jul; 49(14):4057-61. PubMed ID: 2500234
[TBL] [Abstract][Full Text] [Related]
27. [Phase-II-study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases].
Goldhirsch A; Beer M; Sonntag RW; Tschopp L; Cavalli F; Ryssel HJ; Brunner KW
Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1063-7. PubMed ID: 7423151
[TBL] [Abstract][Full Text] [Related]
28. Phase II evaluation of metoprine in patients with non-small-cell lung carcinoma.
Lynch GR; Gralla RJ; Kelsen DP; Casper ES; Stoopler MB; Golbey RB
Cancer Clin Trials; 1981; 4(3):273-6. PubMed ID: 6974611
[TBL] [Abstract][Full Text] [Related]
29. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma.
Schulman P; Budman DR; Vinciguerra V; Weiselberg L; Abrams S; Degnan T
Cancer Treat Rep; 1982 Jan; 66(1):171-2. PubMed ID: 7053253
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical studies of antineoplaston A5 injections.
Burzynski SR; Kubove E; Burzynski B
Drugs Exp Clin Res; 1987; 13 Suppl 1():37-43. PubMed ID: 3569014
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies.
Ghosh AK; Smith NK; Prendiville J; Thatcher N; Crowther D; Stern PL
Eur Cytokine Netw; 1993; 4(3):205-11. PubMed ID: 8218945
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of retinol in patients with advanced cancer.
Goodman GE
Cancer Treat Rep; 1986 Aug; 70(8):1023-4. PubMed ID: 3731149
[TBL] [Abstract][Full Text] [Related]
34. Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results.
Sarna GP; Figlin RA; Pertcheck M; Altrock B; Kradjian SA
J Biol Response Mod; 1989 Feb; 8(1):16-24. PubMed ID: 2784163
[TBL] [Abstract][Full Text] [Related]
35. Recombinant leukocyte alpha interferon in advanced ovarian carcinoma.
Niloff JM; Knapp RC; Jones G; Schaetzl EM; Bast RC
Cancer Treat Rep; 1985; 69(7-8):895-6. PubMed ID: 4016797
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.
Stadler WM; Rybak ME; Vogelzang NJ
Cancer; 1995 Nov; 76(9):1629-33. PubMed ID: 8635068
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of recombinant human tumor necrosis factor-alpha in patients with advanced malignancies.
Bartsch HH; Nagel GA; Mull R; Flener R; Pfizenmaier K
Mol Biother; 1988; 1(1):21-9. PubMed ID: 3267369
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.
Belani CP; Eisenberger M; Van Echo D; Hiponia D; Aisner J
Cancer Treat Rep; 1987 Nov; 71(11):1099-100. PubMed ID: 2824047
[No Abstract] [Full Text] [Related]
39. Phase I clinical trial of an MAF-containing lymphoblastoid cell line supernatant.
Reynolds RD; McEntire JE; Rodes ND; Dunn PA; Walter J; Doyle MK; Anson NO; Garcia A; Oxenhandler RW; Khojasteh A
J Biol Response Mod; 1986 Apr; 5(2):129-39. PubMed ID: 3525761
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of low doses of alpha interferon in patients with breast cancer.
Laszlo J; Hood L; Cox E; Goodwin B
J Biol Response Mod; 1986 Jun; 5(3):206-10. PubMed ID: 3723137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
